CD33 and acute myeloid leukemia: We found that the combination outperformed the killing effect of CAR T cell monotherapy, as indicated by the significantly increased cytotoxicity and apoptosis and decreased survival rate of CD33 + AML cells (all p < 0.01) (Fig. 2A-C, E, F).